# Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

> **NCT04807673** · PHASE3 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 342 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** neoadjuvant chemoradiotherapy

## Key facts

- **NCT ID:** NCT04807673
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2028-05
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2022-06-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807673, "Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04807673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*